Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
Laquinimod - Wikipedia
Teva and Active Biotech Expand Investigational MS Treatment Program
Laquinimod for Relapsing-Remitting Multiple Sclerosis
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | Request PDF
Laquinimod - Wikipedia
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
PDF) Effect of laquinimod on gray matter and white matter atrophy in relapsing-remitting multiple sclerosis: analysis of the BRAVO phase III trial
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva launches personalised digital support for MS patients - PMLiVE
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study - The Lancet
Active Biotech Regains Rights Over Laquinimod from Teva Pharmaceutical
Teva drops development of laquinimod - PharmaTimes
Advances in Oral Drugs for Multiple Sclerosis | Erase MS
Meet the Compound: Laquinimod – HD Insights
Insight into the mechanism of laquinimod action - Journal of the Neurological Sciences
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Multiple Sclerosis Research: Will Teva and Biogen Come together for the sake of DMF, laquinimod polypill
